Literature DB >> 27884064

Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines.

Jean D Sipe1, Merrill D Benson2, Joel N Buxbaum3, Shu-Ichi Ikeda4, Giampaolo Merlini5, Maria J M Saraiva6, Per Westermark7.   

Abstract

The Nomenclature Committee of the International Society of Amyloidosis (ISA) met during the XVth Symposium of the Society, 3 July-7 July 2016, Uppsala, Sweden, to assess and formulate recommendations for nomenclature for amyloid fibril proteins and the clinical classification of the amyloidoses. An amyloid fibril must exhibit affinity for Congo red and with green, yellow or orange birefringence when the Congo red-stained deposits are viewed with polarized light. While congophilia and birefringence remain the gold standard for demonstration of amyloid deposits, new staining and imaging techniques are proving useful. To be included in the nomenclature list, in addition to congophilia and birefringence, the chemical identity of the protein must be unambiguously characterized by protein sequence analysis when possible. In general, it is insufficient to identify a mutation in the gene of a candidate amyloid protein without confirming the variant changes in the amyloid fibril protein. Each distinct form of amyloidosis is uniquely characterized by the chemical identity of the amyloid fibril protein that deposits in the extracellular spaces of tissues and organs and gives rise to the disease syndrome. The fibril proteins are designated as protein A followed by a suffix that is an abbreviation of the parent or precursor protein name. To date, there are 36 known extracellular fibril proteins in humans, 2 of which are iatrogenic in nature and 9 of which have also been identified in animals. Two newly recognized fibril proteins, AApoCII derived from apolipoprotein CII and AApoCIII derived from apolipoprotein CIII, have been added. AApoCII amyloidosis and AApoCIII amyloidosis are hereditary systemic amyloidoses. Intracellular protein inclusions displaying some of the properties of amyloid, "intracellular amyloid" have been reported. Two proteins which were previously characterized as intracellular inclusions, tau and α-synuclein, are now recognized to form extracellular deposits upon cell death and thus have been included in Table 1 as ATau and AαSyn.

Entities:  

Keywords:  Amyloid fibril; amyloid protein; amyloidosis; inclusion body; nomenclature

Mesh:

Substances:

Year:  2016        PMID: 27884064     DOI: 10.1080/13506129.2016.1257986

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  140 in total

Review 1.  Imaging of Left Ventricular Hypertrophy: a Practical Utility for Differential Diagnosis and Assessment of Disease Severity.

Authors:  Toru Kubo; Hiroaki Kitaoka
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

2.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

3.  Amyloidosis by Bacterial Infection in Critically Ill Patients?

Authors:  Yvonne S Eisele
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

4.  Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis.

Authors:  Carlo O Martins; Cecilia Lezcano; San S Yi; Heather J Landau; Jessica R Chapman; Ahmet Dogan
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

5.  Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.

Authors:  Taro Yamashita; Mitsuharu Ueda; Yohei Misumi; Teruaki Masuda; Toshiya Nomura; Masayoshi Tasaki; Kotaro Takamatsu; Keiko Sasada; Konen Obayashi; Hirotaka Matsui; Yukio Ando
Journal:  J Neurol       Date:  2017-11-24       Impact factor: 4.849

6.  Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015.

Authors:  Robert A Kyle; Dirk R Larson; Paul J Kurtin; Shaji Kumar; James R Cerhan; Terry M Therneau; S Vincent Rajkumar; Celine M Vachon; Angela Dispenzieri
Journal:  Mayo Clin Proc       Date:  2019-01-31       Impact factor: 7.616

7.  Stabilization of amyloidogenic immunoglobulin light chains by small molecules.

Authors:  Gareth J Morgan; Nicholas L Yan; David E Mortenson; Enrico Rennella; Joshua M Blundon; Ryan M Gwin; Chung-Yon Lin; Robyn L Stanfield; Steven J Brown; Hugh Rosen; Timothy P Spicer; Virneliz Fernandez-Vega; Giampaolo Merlini; Lewis E Kay; Ian A Wilson; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-10       Impact factor: 11.205

8.  Ultrastructure and pathology of prion protein amyloid accumulation and cellular damage in extraneural tissues of scrapie-infected transgenic mice expressing anchorless prion protein.

Authors:  Brent Race; Martin Jeffrey; Gillian McGovern; David Dorward; Bruce Chesebro
Journal:  Prion       Date:  2017-07-31       Impact factor: 3.931

9.  Yellow subconjunctival deposits.

Authors:  Ofira Zloto; Mordechai Rosner; Vicktoria Vishnevskia-Dai
Journal:  BMJ Case Rep       Date:  2019-08-01

10.  Stability of Human Serum Amyloid A Fibrils.

Authors:  Wenhua Wang; Ulrich H E Hansmann
Journal:  J Phys Chem B       Date:  2020-11-16       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.